COVID-2019 immune globulins (Equine) - Emergent BioSolutions
Alternative Names: Anti-SARS-CoV-2 immune globulin intravenous (Equine); COVID-19 immune globulins (Equine); COVID-EIGLatest Information Update: 28 Nov 2023
At a glance
- Originator Emergent BioSolutions
- Class Antivirals; Immunoglobulin fragments
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (Parenteral)
- 27 Oct 2020 Phase-I clinical trials in COVID-2019 infections in USA (Parenteral) (Emergent BioSolutions pipeline, October 2020)
- 27 Jul 2020 Emergent BioSolutions plans a phase II trial for COVID-2019 infections (Parenteral) in 2020
Development Overview
Introduction
Equine-derived purified immune globulin fragments, derived from polyclonal antibodies, designated as COVID EIG, is being developed by Emergent BioSolutions, for the treatment of severe COVID-2019 infections. The company has utilised its hyperimmune platform which allows the isolation of purified immune globulin fragments from polyclonal antibodies which are specific for SARS-CoV-2 antigens from immunised horses. Hyperimmunes are polyclonal antibody therapeutics derived from plasma that leverage the immune response in humans and can provide protection from the infection. Early clinical development is underway in the US.
As at November 2023, no recent reports of development had been identified for phase-I development in COVID-2019-infections in USA (Parenteral).
Key Development Milestones
As of October 2020, phase I trial is ongoing for the treatment of severe COVID-2019 infections (Emergent BioSolutions pipeline, October 2020).
As of May 2020, Emergent BioSolutions is conducting preclinical trials for the treatment of severe COVID-2019 infections (Emergent BioSolutions pipeline, May 2020).
In March 2020, Emergent BioSolutions reported initiation of plasma collection from horses in order to isolate and manufacture antibodies against SARS-CoV-2 virus [1] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antivirals, Immunoglobulin fragments
- Mechanism of Action Immunomodulators
-
WHO ATC code
J06B (Immunoglobulins)
-
EPhMRA code
J6H (Specific Immunoglobulins - Antiviral)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (I) | USA | Parenteral / unspecified | Emergent BioSolutions | 28 Nov 2023 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Emergent BioSolutions | Originator | USA |
| Emergent BioSolutions | Owner | USA |
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 31 Dec 2020 | Trial Update | Emergent BioSolutions plans a phase II trial for COVID-2019 infections (Parenteral) in 2020 (700320080) [2] | 29 Jul 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Nov 2023 | Phase Change - No development reported | No recent reports of development identified for phase-I development in COVID-2019-infections in USA (Parenteral) Updated 28 Nov 2023 |
| 27 Oct 2020 | Phase Change - I | Phase-I clinical trials in COVID-2019 infections in USA (Parenteral) (Emergent BioSolutions pipeline, October 2020) Updated 30 Oct 2020 |
| 27 Jul 2020 | Trial Update | Emergent BioSolutions plans a phase II trial for COVID-2019 infections (Parenteral) in 2020 [2] Updated 29 Jul 2020 |
| 29 May 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019 infections in USA (Parenteral), prior to May 2020 (Emergent BioSolutions pipeline, May 2020) Updated 29 May 2020 |
| 11 Mar 2020 | Phase Change | Early research in COVID-2019 infections in USA (Parenteral) [1] Updated 19 Mar 2020 |
References
-
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease.
Media Release -
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG